Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 is Administered in Combination With IV Modified FOLFIRINOX (mFFX) With or Without IV Budigalimab Compared to mFFX in Adult Participants With Untreated Pancreatic Cancer Metastasis

Austin Health /ID# 231378, Heidelberg

Monash Medical Centre /ID# 231379, Clayton

Johns Hopkins Hospital /ID# 226713, Baltimore

Hospital Universitario 12 de Octubre /ID# 230102, Madrid

Univ Hosp Cleveland /ID# 226807, Cleveland

Cleveland Clinic Main Campus /ID# 231135, Cleveland

Hospital Universitario Miguel Servet /ID# 230139, Zaragoza

Rambam Health Care Campus /ID# 229555, Haifa

The Chaim Sheba Medical Center /ID# 226812, Ramat Gan

UCHSC Anschultz Cancer Pavilion /ID# 227841, Aurora

Penn State Hershey Medical Ctr /ID# 229837, Hershey

Pan American Center for Oncology Trials, LLC /ID# 228210, Rio Piedras

Yonsei University Health System Severance Hospital /ID# 230280, Seoul

Asan Medical Center /ID# 230282, Seoul

Hospital Universitario Vall d'Hebron /ID# 230226, Barcelona